The rapid pace of change in the AI landscape means the bar for founders has been raised significantly. To build a great company today, investors find that an entrepreneur must be far more capable and closer to the top 0.1% than in previous tech cycles.
Oak's flexible fund structure enables a "lifecycle investor" model, writing checks from $1M to $100M. For high-potential companies like Augur, they can commit the full $100M upfront, giving founders long-term capital security and strategic alignment from the beginning.
A growing number of early-stage startups are recognizing they've built a valuable product or feature, but not a sustainable standalone business. This is leading to an increase in mergers between smaller companies, where one's product is integrated into another's larger platform.
While backing successful repeat founders is a common VC strategy, the true measure of a firm's value is when those founders actively choose to partner with them again for their next venture. This signifies a relationship built on trust and strategic value, not just capital.
While the AI boom has created massive opportunities, only about 10% of companies have a large enough TAM to justify their high valuations. The other 90% are niche players that will ultimately be acquired based on traditional EBITDA multiples, not strategic tech premiums.
Over the last four years, China has become a life sciences powerhouse, capturing 50% of U.S. pharma's outsourced research spend. This rapid shift, combined with their patent output, threatens America's leadership in biotech and drug development.
By combining a Medicare Advantage plan, a proprietary tech platform, and a primary care network, Devoted Health created a defensible moat. This vertical integration allows AI to drive dramatic efficiency gains, tripling company size while halving operating ratio.
The true value of AI in clinical settings isn't replacing doctors, but eliminating administrative work, which accounts for 25-30% of healthcare costs. This allows clinicians to stop focusing on data entry and turn their attention back to the patient, directly improving care.
For a decade, AI failed to produce developable therapeutics. In the last two years, however, new models have matured, making AI-driven drug design and discovery an explosive and attractive investment area for the first time.
A pivotal moment in Annie Lamont's career was being told her bar for entrepreneurs wasn't high enough. This advice forced a shift from a thesis-first to a people-first investment strategy, underscoring that backing exceptional individuals must be the primary filter for any deal.